|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Symdeko
gptkb:CFTR_modulators
|
|
gptkbp:activities
|
CFTR modulator
|
|
gptkbp:affiliated_with
|
gptkb:Ivacaftor
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Symdeko
|
|
gptkbp:can_be_used_with
|
gptkb:Ivacaftor
gptkb:Lumacaftor
|
|
gptkbp:class
|
gptkb:Cystic_fibrosis_transmembrane_conductance_regulator_(CFTR)_modulators
|
|
gptkbp:clinical_trial
|
Phase 3
ongoing studies
treatment of cystic fibrosis
|
|
gptkbp:collaborations
|
with academic institutions
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
hypersensitivity to tezacaftor
|
|
gptkbp:developed_by
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:education
|
important for understanding therapy
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:future_plans
|
focused on new formulations
|
|
gptkbp:has_programs
|
available for patients
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tezacaftor
|
|
gptkbp:indication
|
homozygous F508del mutation
|
|
gptkbp:ingredients
|
C22 H26 F2 N2 O3 S
|
|
gptkbp:interacts_with
|
CY P3 A inducers
CY P3 A inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
R07 AX
|
|
gptkbp:is_monitored_by
|
pulmonary function tests
liver function tests
|
|
gptkbp:is_used_for
|
gptkb:cystic_fibrosis
|
|
gptkbp:manager
|
gptkb:tablet
oral
|
|
gptkbp:marketed_as
|
gptkb:Symdeko
|
|
gptkbp:pharmacokinetics
|
oral bioavailability
CFTR function improvement
|
|
gptkbp:population
|
adults and children over 12
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_information_on
|
included in treatment guidelines
|
|
gptkbp:receives_funding_from
|
supported by grants
|
|
gptkbp:research_focus
|
CFTR modulation
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:scholarships
|
available through manufacturers.
|
|
gptkbp:shelf_life
|
2 years
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
nasal congestion
diarrhea
skin rash
elevated liver enzymes
respiratory symptoms
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:supports
|
granted in the US
granted in the EU
|
|
gptkbp:targets
|
CFTR protein
|
|
gptkbp:type_of
|
210349-80-5
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:type_of_insurance
|
varies by plan
|
|
gptkbp:weight
|
420.52 g/mol
|